Please assess the completion status of the following clinical trial:

Trial Title: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven adenocarcinoma of the prostate~* Prior local therapy for prostate cancer~* Biochemical recurrence or clinical progression after local therapy (PSA \> 0.2 µg/l),~* PSA-DT \< 6 months~* Gallium-68 (68Ga)-PSMA-PET-CT positive metastases in bones and/or lymph nodes (N1/M1ab): ≥1, maximally 10 metastases (at least 1 lesion with a lesion size of ≥1 cm to enable adequate dosimetry studies)~* Local treatment for oligo-metastases with radiotherapy or surgery appears to be no option anymore (due to prior treatment or the location of the metastatic lesions)~* No prior hormonal therapy or chemotherapy; testosteron \> 1.7 nmol/l. Exception: local prostate cancer treated with local radiotherapy plus adjuvant ADT; these patients need to be stopped with ADT at least 3 months~* No visceral metastases~* Laboratory values:~  * White blood cells \> 3.5 x 109/l~ * Platelet count \> 150 x 109/l~ * Hemoglobin \> 6 mmol/l~ * Alanine transaminase, aspartate aminotransferase \< 3 x upper limit of normal~ * Modification of Diet in Renal Disease Study glomerular filtration rate ≥ 60 ml/min~* Signed informed consent~Exclusion Criteria:~* No detectable lesions on the Ga-68 PSMA PET/CT with an uptake level below the liver uptake.~* A known subtype other than prostate adenocarcinoma~* Any medical condition present that in the opinion of the investigator will affect patients' clinical status when participating in this trial.~* Prior hip replacement surgery potentially influencing performance of PSMA PET/CT and nano Magnet Resonance Tomography (nMRI)~* Contra-indication for MRI imaging (claustrophobia, implanted electric and electronic devices (heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators), intracranial metal clips, metallic bodies in the eye)~* Contra-indication for Buscopan (allergy to hyoscine or any other ingredients of this medication, allergy to to other atropines (e.g. atropine, scopolamine), myasthenia gravis, enlarged colon, glaucoma or obstructive prostatic hypertrophy)~* Additional contra-indications for the intravenous injection form of Buscopan (taking blood thinning medication (e.g. warfarin, heparin), narrowing of the gastrointestinal tract, fast heartbeat, angina or heart failure)~* Contra-indication to glucagon (pheochromocytoma)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lu-177 PSMA-617 (Type: EXPERIMENTAL): Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)

Based on this trial design, predict the completion outcome and termination type (if applicable).